Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 GABA in epilepsy: the pharmacologic basis.

Literature DB >> 2548836

GABA in epilepsy: the pharmacologic basis.

Abstract

GABA transmission plays a key role in controlling seizure activity. The precise nature of its effect depends on the particular location in the brain and the pathway involved. Animal studies have helped to define specific brain regions such as the substantia nigra and area tempestas that are critical in controlling seizure activity. Antiepileptic drugs such as vigabatrin [gamma vinyl GABA (GVG)], a drug rationally developed to treat resistant epilepsy, can enhance GABA transmission in these regions and may thereby afford seizure protection.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1989 PMID： 2548836 DOI： 10.1111/j.1528-1157.1989.tb05825.x

Source DB: PubMed Journal: Epilepsia ISSN： 0013-9580 Impact factor: 5.864

Keyword Cloud
Cited

17 in total

1. The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

Authors: Richard B Silverman
Journal: J Med Chem Date: 2012-01-10 Impact factor: 7.446

2. Frontal cortex lesion prior to hyperglycemic ischemia: no decrease in ensuing substantia nigra pars reticulata damage or fatal post-ischemic seizures.

Authors: J Lundgren; M Ingvar; M L Smith; B K Siesjö
Journal: Exp Brain Res Date: 1992 Impact factor: 1.972

GABA in epilepsy: the pharmacologic basis.

1. The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile spasms.

2. Frontal cortex lesion prior to hyperglycemic ischemia: no decrease in ensuing substantia nigra pars reticulata damage or fatal post-ischemic seizures.

Review 3. Ornithine aminotransferase versus GABA aminotransferase: implications for the design of new anticancer drugs.

4. Design and mechanism of tetrahydrothiophene-based γ-aminobutyric acid aminotransferase inactivators.

5. Fluorinated conformationally restricted gamma-aminobutyric acid aminotransferase inhibitors.

6. Synthesis and evaluation of novel aromatic substrates and competitive inhibitors of GABA aminotransferase.

Review 7. GABA neurons in seizure disorders: a review of immunocytochemical studies.

8. Gamma-aminobutyrate aminotransferase activity in brains of schizophrenic patients.

9. Effects of the GABA-uptake inhibitor tiagabine in rat globus pallidus.

10. Changes of NMDA receptor binding in spontaneously epileptic rat and parent strains.